The FDA's decision Wednesday means patients in the United States will soon have access to a second daily oral medication to treat obesity and weight-related issues.
U.S. childhood and teen obesity rates have reached record-highs while adult obesity rates may be slowing, according to two new reports published early Wednesday by the Centers for Disease Control and Prevention (CDC).
As Super Bowl Sunday approaches, the battle off the field for advertisers to win over 120 million-plus viewers will be just as heated as the rivalry between the New England Patriots and Seattle Seahawks.
Novo Nordisk announced FDA approval of a new Wegovy pill, the first GLP-1 drug approved for oral use.
The first and only oral GLP-1 for weight loss in adults is now available to consumers.